Skip to content

Investigating the effect of bromelain on primary dysmenorrhea pain

Comparing the effect of bromelain and placebo on primary dysmenorrhea pain on female students

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20160813029327N23
Enrollment
90
Registered
2024-07-01
Start date
2024-08-22
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary dysmenorrhea. Primary dysmenorrhea

Interventions

Intervention 1: Intervention group: Receives Anaheal capsules GDU500 (containing 200 mg bromelain GDU/g 2500) producted by Salamat Parmoon Amin pharmaceutical company. Capsules will be given to patien

Sponsors

Salamat Parmoon Amin pharmaceutical company
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 25 Years

Inclusion criteria

Inclusion criteria: Being diagnosed with primary dysmenorrhea Age between 18-25 years old BMI between 19-25 Having the score of 5-8 in VAS Having regular menstrual cycles

Exclusion criteria

Exclusion criteria: Being diagnosed with secondary dysmenorrhea Using medications that might interact with NSAIDs Being on oral contraceptive pills Having allergy or sensitive reaction to herbal products of pineapple, carrot, celery and anise History of abdomen or pelvic surgery Contraindication of herbal drugs and NSAIDs (like having renal, hepatic or GI problems) Suffering from chronic illnesses such as diabetes, CKD, hepatic failure) Having sign and symptoms of itching, burning sensations and unnormal vaginal discharge Having pelvic inflammatory diseases Having tumor or fibrosis Having stress in the past 6 months Having endometriosis Patients with IUD Patients who started a specific regimen or vegetarian diet throughout the study Events happened that caused acute stress

Design outcomes

Primary

MeasureTime frame
Pain score of patients with primary dysmenorrhea. Timepoint: Before starting the intervention in the first cycle, then the second and third cycles each in the first 3 days. Method of measurement: VAS (Visual Analogue Scale).

Secondary

MeasureTime frame
Investigating various distressing states in patients with primary dysmenorrhea. Timepoint: Before starting the intervention in the first cycle, then the second and third cycles each in the first 3 days. Method of measurement: MMDQ= Moos Menstrual Distress Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfsaneh Ekhtiari

Islamic Azad University

Afsanehekhtiari@gmail.com+98 21 3334 8036

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026